Weight Loss News Center
|
|
Weight Control News & InformationA Thought Leader Analysis into Alcoholism and Future Competitive Growth in the Drug Development Market (Business Wire via Yahoo! Finance) DUBLIN, Ireland----Research and Markets has announced the addition of the "Thought Leader Insight & Analysis: Alcoholism" report to their offering.One pill to make you slimmer? (Provo Daily Herald)For an activity that seems to come so naturally to so many Americans, getting fat is actually quite complicated. Not surprisingly, then, so is developing a pill that will help reverse that process. Controversial obesity drug gets UK okay (Reuters via Yahoo! News) Sanofi-Aventis won a final green light for its obesity drug Acomplia from Britain's cost-effectiveness watchdog NICE on Wednesday, clearing the way for doctors to prescribe it on the state health service. NHS approves weight-loss drug banned in America over suicide fears (Evening Standard)A weight-loss drug banned in the U.S. over fears it can heighten the risk of suicide has been given the go-ahead in Britain. Acomplia will be available to overweight or obese patients who cannot take, or who have had no success with, the two other weight-loss drugs available on the Health Service. Obesity drug rejected by Scottish NHS to be available in England and Wales (The Herald)An obesity drug rejected for use by the Scottish NHS will be available on prescription in England and Wales. Early trials have shown the treatment rimonabant, which suppresses appetite, could help patients lose up to 10% of their body weight. NHS approves weight-loss drug banned in America over suicide fears (Daily Mail)A weight-loss drug banned in the U.S. over fears it can heighten the risk of suicide has been given the go-ahead in Britain. Acomplia will be available to overweight or obese patients. New Obesity Treatment Option For NHS Patients As It Emerges Public Want Doctors To Help Obese Patients Lose Weight, UK (Medical News Today)The National Institute for Health and Clinical Excellence (NICE) has issued new guidance recommending use of AcompliaŽ (rimonabant) in England and Wales, within its licensed indications, as an adjunct to diet and exercise for adults who are obese or overweight and who have had an inadequate respo
| |